Zoetis (NYSE:ZTS) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Zoetis (NYSE:ZTS) posted its earnings results on Thursday. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03, Zacks reports. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis updated its FY 2025 guidance to 6.000-6.100 EPS.

Zoetis Trading Down 4.5 %

Shares of ZTS traded down $7.40 during mid-day trading on Friday, reaching $157.54. The stock had a trading volume of 7,656,606 shares, compared to its average volume of 2,578,743. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The business’s fifty day moving average is $168.51 and its 200 day moving average is $178.81. The firm has a market cap of $71.08 billion, a price-to-earnings ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

Several brokerages recently commented on ZTS. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday. Piper Sandler cut their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $214.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.